## ABVX: Abivax SA - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 11.0% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($118.57)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. French biotech Abivax's shares climb on Eli Lilly bid rumors**
- Source: TradingView | 20251210T130903 | Bullish | Relevance: 99%
-  Shares of French biotech company Abivax (ABVX) surged over 20% on Wednesday due to market rumors suggesting a potential takeover bid by U.S. pharma giant Eli Lilly (LLY). Both companies declined to comment on the speculation, which comes after Abivax reported positive Phase 3 trial results in July for its key drug obefazimod, causing its Paris-listed shares to soar and its market valuation to reach over 8 billion euros.

**2. Abivax (NASDAQ:ABVX) Reaches New 52-Week High - Should You Buy?**
- Source: MarketBeat | 20251210T160903 | Bullish | Relevance: 99%
- Abivax (NASDAQ:ABVX) hit a new 52-week high of $137.00, trading strongly at $134.699 with a $10.62 billion market cap. Wall Street analysts maintain a "Moderate Buy" rating with an average $123.00 price target, with Guggenheim raising its objective to $150. The biotech company is developing obefazimod for ulcerative colitis and has seen increased institutional holdings despite negative EPS forecasts.

**3. Abivax Unexpected Surge: Market Analysis**
- Source: www.timothysykes.com | 20251210T190919 | Bullish | Relevance: 99%
-  Abivax SA stock has experienced a significant surge, trading up by 5.02% due to promising results from its innovative immunological drug, obefazimod, and positive market sentiment ahead of upcoming Phase 2b induction topline results for Crohnâ€™s disease in late 2026. The company's strong financial overview, including $812M in operating revenue and $207M in net income, coupled with market anticipation for new drug data, underpins this recent stock performance. While the high price-to-book ratio and enterprise value suggest potential overvaluation, the market is reacting positively to Abivax's biopharmaceutical advancements, indicating cautious optimism among investors.

**4. What's Happening With French Biotech Abivax Stock On Wednesday?**
- Source: Benzinga | 20251210T180903 | Bullish | Relevance: 98%
-  Abivax SA's stock is trading higher on Wednesday due to market rumors of a potential takeover by U.S. pharma giant Eli Lilly and Co. The company's stock has surged over 1,500% in the past six months, driven significantly by positive Phase 3 trial results for its ulcerative colitis treatment, obefazimod. Eli Lilly has also been speculated to be preparing for other major acquisitions, including Viking Therapeutics Inc.

**5. Abivax Sees Unusually Large Options Volume (NASDAQ:ABVX)**
- Source: MarketBeat | 20251209T160928 | Bullish | Relevance: 98%
-  Abivax (NASDAQ:ABVX) experienced unusually large options trading volume on Tuesday, with traders purchasing 3,575 call options, an 82% increase over the daily average. This activity comes as analysts have raised price targets and ratings, with a consensus "Moderate Buy" rating and an average target of $123. The clinical-stage biotech is advancing its lead drug obefazimod in Phase 3 trials for ulcerative colitis, and its shares traded up about 5.9% to $121.85 amid the increased interest.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Truist Securiti | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Truist Securiti | init | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- TCG Crossover Manage: 9.1% (+17.4%)
- UBS Group AG: 5.7% (+2561.0%)
- Darwin Global Manage: 4.1% (+100.0%)
- Point72 Asset Manage: 3.8% (+1642.4%)
- Cormorant Asset Mana: 2.5% (-8.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +16.7% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Revenue growth strong at 721% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.5B |
| Beta | -0.11 |
| 52W Range | $4.77 - $138.49 |
| Short Interest | 3.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -5.7% to 11.0% (+16.7% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (11.0% > 6.0%), caution on chasing. MRS_5 at 8.5% confirms short-term momentum alignment. Outperforming sector by 13.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 10.98% (CS: 98) | Strong |
| RSI_14 | 69.8 | Neutral |
| MACD Histogram | 0.32 | Bullish |
| vs SMA20 | 1.124x | Above |
| vs SMA50 | 1.273x | Above |
| vs SMA200 | 2.717x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $133.09
- **Stop Loss:** $118.57 (10.9% risk)
- **Target:** $147.61 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 95
- **Position Value:** $12,643.55
- **Portfolio %:** 12.64%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-03-23 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*